About Us - Drug Development Technology

Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Advertise with us

APIs

Vaccine development: the need for speed

Lack of CMO availability threatens cell and gene therapy development

Novaliq’s NovaTears+Omega-3 represents the first-in-class omega-3-containing eye drop for evaporative dry eye

Approvals

September’s top news stories

Will the UK relax its current regulations for cannabis-based products?

CAR-T toxicity rating system to be finalized by ASBMT by year-end

Clinical Research

Aimmune Therapeutics begins Phase II trial of AR101 and dupilumab

September’s top news stories

Will the UK relax its current regulations for cannabis-based products?

Clinical Trials

Amplyx doses first patient in Phase II APX001 study

Calliditas enrols first patient in Phase III study of Nefecon

Nightstar to start Phase II/III trial of NSR-RPGR for XLRP

Diseases

Data from NIH-funded trial offers hope for gonorrhoea treatment

Aevi Genomic Medicine completes enrolment for Part B of ASCEND trial

Tolero enrols first patient in Phase Ib/II trial of alvocidib

Genomics & Proteomics

August’s top news stories

July’s top news stories

June’s top news stories

Market Data

Deals this week: OSE Immunotherapeutics, Tango Therapeutics, Provention Bio

Deals this week: AgaMatrix, Kissei Pharmaceutical, 89Bio

Deals this week: Kazia Therapeutics, Zymeworks, CANbridge

Technology

September’s top news stories

August’s top news stories

July’s top news stories

Online

Read more

In Print

Read more